Background
Amplo Biotechnology, founded in 2019, is a privately held U.S.-based biotech company dedicated to developing Adeno-Associated Virus (AAV)-based gene therapies targeting diseases of the neuromuscular junction (NMJ). The company's mission is to create potentially curative treatments for conditions such as congenital myasthenic syndromes (CMS), aiming to address severe health issues including paralysis, breathing, and swallowing difficulties.
Key Strategic Focus
Amplo Biotechnology's strategic focus centers on the development of AAV gene therapies for NMJ disorders. Their lead program, AMP-101, is an AAV-Dok7 gene therapy designed to treat Dok-7 CMS by delivering the Dok-7 protein, essential for NMJ development and maintenance. Additionally, AMP-101 has shown potential applications in conditions like Emery-Dreyfuss Muscular Dystrophy, Amyotrophic Lateral Sclerosis (ALS), and age-related muscle function decline. Another key program, AMP-201, targets ColQ CMS through AAV-mediated delivery of the Collagen Q protein, crucial for normal skeletal muscle function.
Financials and Funding
In October 2021, Amplo Biotechnology closed a Series Seed financing round led by BioBrit, LLC., with participation from Casdin Capital, SeedFolio, and other biotech angel investors. The funding was allocated to advance AMP-101 to large-scale manufacturing and complete Investigational New Drug (IND)-enabling studies. Additionally, the company secured a National Institutes of Health (NIH) Fast-Track Phase I/II Small Business Innovation Research (SBIR) grant for AMP-101 development. In May 2023, Amplo received further funding from the NIH and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to support AMP-201's development.
Pipeline Development
- AMP-101 (AAV-Dok7 Gene Therapy): Designed to treat Dok-7 CMS, AMP-101 has demonstrated efficacy in preclinical models, including reversal of age-related muscle function loss and increased survival in ALS and Emery-Dreyfuss Muscular Dystrophy mouse models. The company plans to initiate clinical trials for Dok-7 CMS in 2023, with potential expansion into other neuromuscular conditions upon demonstrating initial safety and efficacy.
- AMP-201 (AAV-Collagen Q Gene Therapy): Targeting ColQ CMS, AMP-201 is in the preclinical stage, with plans to submit a clinical trial application within 10-12 months.
Technological Platform and Innovation
Amplo Biotechnology leverages AAV-based gene therapy platforms to deliver therapeutic genes directly to muscle tissues, addressing the underlying genetic causes of NMJ disorders. By utilizing established delivery technologies and manufacturing methods, the company aims to mitigate risks associated with novel therapeutic development.
Leadership Team
- Patricio Sepulveda, Ph.D., MBA – Chief Executive Officer: Co-founder of Amplo Biotechnology, Dr. Sepulveda brings extensive experience in biotechnology and gene therapy development.
- Al Hawkins – President: As co-founder and President, Mr. Hawkins contributes significant expertise in biotech operations and strategic development.
- Dan Bradbury – Executive Chair: Appointed Chair of the Board in October 2021, Mr. Bradbury provides leadership and guidance, drawing from his background in biotech investment and management.
- Claudia Canzonetta – Program Director: Ms. Canzonetta oversees program development, ensuring alignment with the company's strategic objectives.
Leadership Changes
In October 2021, Dan Bradbury was appointed Executive Chair of the Board, coinciding with the closing of the Series Seed financing round.
Competitor Profile
- Market Insights and Dynamics: The gene therapy market for neuromuscular disorders is experiencing significant growth, driven by advancements in genetic research and increasing demand for effective treatments.
- Competitor Analysis:
- NMD Pharma: A Danish company developing small molecule therapies for neuromuscular disorders, focusing on enhancing neuromuscular transmission.
- REGENXBIO Inc.: A U.S.-based firm specializing in AAV gene therapies for various genetic diseases, including neuromuscular conditions.
- Aevitas Therapeutics: A subsidiary of Fortress Biotech, focusing on AAV-based gene therapies for complement-mediated diseases.
- Chameleon Biosciences: Developing next-generation AAV vectors with reduced immune response for gene therapy applications.
- Tenaya Therapeutics: A biopharmaceutical company targeting heart disease through gene therapy and regenerative medicine approaches.
Strategic Collaborations and Partnerships
Amplo Biotechnology collaborates with leading NMJ experts and institutions to advance its gene therapy programs. Notably, AMP-101 was developed in partnership with Professor Yuji Yamanashi's group at the Institute of Medical Science, University of Tokyo.
Operational Insights
Amplo's strategic focus on NMJ disorders, combined with its use of established AAV delivery technologies, positions the company to efficiently develop therapies for rare and ultra-rare patient populations. This approach differentiates Amplo from competitors by emphasizing risk mitigation and capital efficiency.
Strategic Opportunities and Future Directions
Amplo Biotechnology aims to expand its gene therapy pipeline beyond CMS to address a broader range of neuromuscular conditions. By demonstrating the safety and efficacy of AMP-101 and AMP-201, the company seeks to establish a strong foothold in the gene therapy market for NMJ disorders and explore potential applications in related diseases.
Contact Information
- Website: amplobiotechnology.com
- Email: commdev@amplobiotechnology.com
- Headquarters: Pompano Beach, FL, USA
